TetraLogic Pharmaceuticals Corporation (NasdaqGM:TLOG) will seek acquisitions. TetraLogic announced the pricing of its offering of $47 million in aggregate principal amount of convertible senior notes. TetraLogic estimates that the net proceeds from this offering will be approximately $44 million after deducting the initial purchasers' discounts and commissions and the estimated offering expenses, it intends to use the net proceeds to finance clinical and preclinical development activities for birinapant and suberohydroxamic acid phenyl ester (SHAPE), for potential future in-licensing and for working capital and general corporate purposes, which may include payment of interest and acquisitions.